Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details

This article is part of the supplement: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection .

Open AccessOral presentation

O123 To overdose or underdose? The question of Kaletra in children in the UK/Irish Collaborative HIV Paediatric Study (CHIPS)

AS Walker1, KL Boyd1, K Doerholt2, H Lyall3, E Menson4, K Butler5, P Tookey6, A Riordan7, D Shingadia8, A Judd1, G Tudor-Williams3 and DM Gibb1

MRC Clinical Trials Unit, London, UK

Bristol Royal Hospital for Children, Bristol, UK

St Mary's Hospital, London, UK

Evelina Children's Hospital, London, UK

Our Lady's Hospital for Sick Children, Dublin, Ireland

Institute of Child Health, London, UK

Royal Liverpool Children's NHS Trust, Liverpool, UK

Great Ormond Street Hospital for Sick Children, London, UK

corresponding author email

from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008

Journal of the International AIDS Society 2008, 11(Suppl 1):O8doi:10.1186/1758-2652-11-S1-O8

Published: 10 November 2008

First paragraph (this article has no abstract)

The licensed lopinavir/r paediatric total daily dose is 460 mg/m2 without, and 600 mg/m2 with concurrent NNRTIs. The 460 mg/m2 dose without NNRTIs was chosen in preference to 600 mg/m2 in a post-hoc drug-interaction analysis [1]. Excellent VL suppression was also reported (79% <400 c/ml at 48 wks) but was based on the higher 600 mg/m2 dose. Thus, some paediatricians prefer this higher dose regardless of concomitant NNRTI therapy.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.